Cargando…
Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients
Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient molnupiravir use in kidney transplant recipients and hemodialysis patients during the first months of 2022 in Poland. Me...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610487/ https://www.ncbi.nlm.nih.gov/pubmed/36298779 http://dx.doi.org/10.3390/v14102224 |
_version_ | 1784819281661263872 |
---|---|
author | Poznański, Paweł Augustyniak-Bartosik, Hanna Magiera-Żak, Anna Skalec, Karolina Jakuszko, Katarzyna Mazanowska, Oktawia Janczak, Dariusz Krajewska, Magdalena Kamińska, Dorota |
author_facet | Poznański, Paweł Augustyniak-Bartosik, Hanna Magiera-Żak, Anna Skalec, Karolina Jakuszko, Katarzyna Mazanowska, Oktawia Janczak, Dariusz Krajewska, Magdalena Kamińska, Dorota |
author_sort | Poznański, Paweł |
collection | PubMed |
description | Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient molnupiravir use in kidney transplant recipients and hemodialysis patients during the first months of 2022 in Poland. Methods: The retrospective observational cohort study at one kidney transplant center included 36 patients diagnosed with COVID-19 with an automated nucleic acid amplification test on nasopharyngeal swab specimens. All patients received molnupiravir for home-based therapy at a dose of 800 mg every 12 h orally for 5 days. Both kidney transplant recipients (n = 16) and hemodialysis patients (n = 20) presented a lot of comorbidities with a Charlson comorbidity index of 4.1 and 5.1, respectively. Results: Patients presented with fever, cough, and weakness followed by muscle and joint pain. Five kidney transplant recipients experienced acute kidney injury with a rise in serum creatinine level from 0.4 to 1.9 mg/dL. No serious side effects of molnupiravir therapy or interactions with immunosuppressive medications were observed. Symptoms of COVID-19 improved rapidly or resolved within 24–48 h of starting treatment. Conclusion: The study suggests the safety and efficacy of molnupiravir therapy alone early after the onset of SARS-CoV-2 infection, but further investigations should be performed to confirm our preliminary results. To the best of the authors’ knowledge, it is the first published report on molnupiravir use in end-stage kidney disease (ESKD) patients on hemodialysis and the third concerning kidney transplant recipients. |
format | Online Article Text |
id | pubmed-9610487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96104872022-10-28 Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients Poznański, Paweł Augustyniak-Bartosik, Hanna Magiera-Żak, Anna Skalec, Karolina Jakuszko, Katarzyna Mazanowska, Oktawia Janczak, Dariusz Krajewska, Magdalena Kamińska, Dorota Viruses Communication Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient molnupiravir use in kidney transplant recipients and hemodialysis patients during the first months of 2022 in Poland. Methods: The retrospective observational cohort study at one kidney transplant center included 36 patients diagnosed with COVID-19 with an automated nucleic acid amplification test on nasopharyngeal swab specimens. All patients received molnupiravir for home-based therapy at a dose of 800 mg every 12 h orally for 5 days. Both kidney transplant recipients (n = 16) and hemodialysis patients (n = 20) presented a lot of comorbidities with a Charlson comorbidity index of 4.1 and 5.1, respectively. Results: Patients presented with fever, cough, and weakness followed by muscle and joint pain. Five kidney transplant recipients experienced acute kidney injury with a rise in serum creatinine level from 0.4 to 1.9 mg/dL. No serious side effects of molnupiravir therapy or interactions with immunosuppressive medications were observed. Symptoms of COVID-19 improved rapidly or resolved within 24–48 h of starting treatment. Conclusion: The study suggests the safety and efficacy of molnupiravir therapy alone early after the onset of SARS-CoV-2 infection, but further investigations should be performed to confirm our preliminary results. To the best of the authors’ knowledge, it is the first published report on molnupiravir use in end-stage kidney disease (ESKD) patients on hemodialysis and the third concerning kidney transplant recipients. MDPI 2022-10-09 /pmc/articles/PMC9610487/ /pubmed/36298779 http://dx.doi.org/10.3390/v14102224 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Poznański, Paweł Augustyniak-Bartosik, Hanna Magiera-Żak, Anna Skalec, Karolina Jakuszko, Katarzyna Mazanowska, Oktawia Janczak, Dariusz Krajewska, Magdalena Kamińska, Dorota Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients |
title | Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients |
title_full | Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients |
title_fullStr | Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients |
title_full_unstemmed | Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients |
title_short | Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients |
title_sort | molnupiravir when used alone seems to be safe and effective as outpatient covid-19 therapy for hemodialyzed patients and kidney transplant recipients |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610487/ https://www.ncbi.nlm.nih.gov/pubmed/36298779 http://dx.doi.org/10.3390/v14102224 |
work_keys_str_mv | AT poznanskipaweł molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients AT augustyniakbartosikhanna molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients AT magierazakanna molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients AT skaleckarolina molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients AT jakuszkokatarzyna molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients AT mazanowskaoktawia molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients AT janczakdariusz molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients AT krajewskamagdalena molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients AT kaminskadorota molnupiravirwhenusedaloneseemstobesafeandeffectiveasoutpatientcovid19therapyforhemodialyzedpatientsandkidneytransplantrecipients |